|
[1]
|
MOK T S��WU Y L��THONGPRASERT S��et al. Gefitinib or carboplatin-paclitaxel in pul monary adenocarcinoma. N Engl J Med�� 2009��361(10)��947-957.
|
|
[2]
|
ZHOU C�� WU Y L�� CHEN G��et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL�� CTONG-0802)A multicentre�� open-label�� randomised�� phase 3 study. Lancet Oncol��2011��12(8)��735-742.
|
|
[3]
|
HAN J Y�� PARK K�� KIM S W��et al.First-SIGNALFirst-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol�� 2012��30��10����1122-1128.
|
|
[4]
|
MITSUDOMI T�� MORITA S�� YATABE Y��et al.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405)��An open label�� randomised phase 3 trial. Lancet Oncol�� 2010 ��11(2)��121-128.
|
|
[5]
|
MAEMONDO M�� INOUE A�� KOBAYASHI K��et al. Gefitinib or chemotherapy for non small-cell lung cancer with mutated EGFR. N Engl J Med�� 2010�� 362 (25) ��2380 -2388.
|
|
[6]
|
ROSELL R��CARCERENY E�� GERVAIS R�� et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non small-cell lung cancer (EURTAC)��A multicentre�� open-label�� randomised phase 3 trial . Lancet Oncol��2012��13(3)��239-246.
|
|
[7]
|
JANNE P A�� WANG X F�� SOCINSKI M A��et al.Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinomaCALGB 30406. J Clin Oncol�� 2010��28(15s)��7503.
|
|
[8]
|
MASSUTI B�� MORN T�� PORTA R��et al. Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epider- mal growth factor receptor (EGFR) mutationsFinal results of the Spanish Lung Cancer Group (SLCG) trial. J Clin Oncol ��2009�� 27(15s)��8023.
|
|
[9]
|
PAEZ J G�� JNNE P A��LEE J C. et al. EGFR mutuations in lung cancerCorrelation with clinical response to Gefitinib therapy. Science��2004�� 304 (5676)1497-1500.
|
|
[10]
|
WU J Y�� WU S G��YANG C H��et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response . Clin Cancer Res�� 2008�� 14(15)��4877-4882.
|
|
[11]
|
FIDLER M J��MORRISON L E��BASU S�� et al. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patientswith gefitinib therapy. Br J Cancer�� 2011��105(12)��1920-1926.
|
|
[12]
|
SOS M L�� KOKER M��WEIR B A�� et al. PTEN Loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res��2009��69 (8)��3256- 3261.
|
|
[13]
|
SUDA K�� TOMIZAWA K�� MITSUDOMI T. Biological and clinical significance of KRAS mutations in lung cancerAn oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev��2010��29(1)��49-60.
|
|
[14]
|
TSAO M�� ZHU C A�� SAKURADA��et al.An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol�� 2006��24(18S) ��7005.
|
|
[15]
|
EBERHARD D A�� JOHNSON B E�� AMLER L C�� et al.Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol�� 2005 ��23(25)��5900-5909.
|
|
[16]
|
CRYSTAL A S�� SHAW A T. New targets in advanced NSCLCEML4-ALK. Clin Adv Hematol Oncol�� 2011�� 9(3)207-214.
|
|
[17]
|
SHAW A T�� YEAP B Y�� MINO-KENUDSON M�� et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol�� 2009 ��27(26)��4247-4253.
|
|
[18]
|
MARCHETTI A�� FELICIONI L�� MALATESTA S�� et al.Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol�� 2011��29(26)��3574-3579.
|
|
[19]
|
KOBAYASHI S�� BOGGON T J�� DAYARAM T�� et al. EGFR Mutation and resistance of non small-cell lung cancer to gefitinib. N Engl J Med��2005��352(8)��786-792.
|
|
[20]
|
WU Y L�� MOK T S�� CHEN H��et al. T790M mutation and c-MET amplification might be correlated to TTP of EGFR-TKI in NSCLC. J Clin Oncol�� 2008��26��8107.
|
|
[21]
|
TURKE A B�� ZEJNULLAHU K�� WU Y L. et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC.Cancer Cell�� 2010��17(1)��77-88.
|
|
[22]
|
KOSAKA T�� YAMAKI E�� MOGI A�� et al. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol�� 2011��2011165-214.
|
|
[23]
|
URAMOTO H�� IWATA T�� ONITSUKA T�� et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res��2010��30(7)2513-2517.
|
|
[24]
|
SEQUIST L V�� WALTMAN B A�� DIAS-SANTAGATA D��et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med�� 2011�� 3(75)��75-26.
|
|
[25]
|
GUIX M�� FABER A C�� WANG S E��et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest�� 2008��118(7)��2609 -2619.
|
|
[26]
|
KAIRA K�� NAITO T�� TAKAHASHI T��et al. Pooled analysis of the reports of erlotin -ib after failure of gefitinib for non-small cell lung cancer. Lung Cancer��2010��68(1)��99-104.
|
|
[27]
|
HATA A�� KATAKAMI N�� YOSHIOKA H��et al.Erlotinib after gefitinib failure in relapsed non-small cell lung cancerClinical benefit with optimal patient selection. Lung Cancer��2011��74(2)268-273.
|
|
[28]
|
WU J Y�� SHIH J Y�� YANG C H�� et al.Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer[J]. Int J Cancer�� 2010��126(1)��247-255.
|
|
[29]
|
FAN Y�� HUANG Z Y�� YU H F�� et al. Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI. Chin J Oncol(�л�������־)�� 2010��32(11)��859- 863.
|
|
[30]
|
MILLER V A�� HIRSH V�� CADRANEL J�� et al.�� Phase IIB/III double-blind randomized trial of Afatinib (BIBW2992�� irreversible inhibitor of EGFR/HER1 and HER2) + Best supportive care versus placebo and BSC in patients failing 1-2 lines of chemotherapy and Erlotinib or Gefitinib (LUX-Lung 1). Lancet Oncol�� 2012��13��5����528-538.
|
|
[31]
|
SPIGEL D R�� ERVIN T J�� RAMLAU R��et al .Final efficacy results from OAM4558g�� a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol��2011��29(15)��7505.
|
|
[32]
|
BERTINO E M�� ZHAO W�� VILLALONA-CALERO M. A��et al.EML4-ALK in NSCLCThe OSU Experience. J Clin Oncol��2011��29��18014.
|
|
[33]
|
HERBST R S�� BLUMENSCHEIN J R G R�� KIM E S�� et al.Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol��2010�� 28(15s)��7609.
|
|
[34]
|
SCAGLIOTTI G�� NOVELLO S�� VON PAWEL J�� et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer . J Clin Oncol�� 2010�� 28(11)1835-1842.
|
|
[35]
|
SPIGEL D R�� BURRIS HAR D�� GRECO F A��et al.Randomized�� double-blind�� placebo -controlled�� phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non small-cell lung cancer. J Clin Oncol��2011��29(18)��2582-2589.
|
|
[36]
|
RHO J K��CHOI Y J��JEON B S��et al. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther��2010��9(12)��3233-3243.
|
|
[37]
|
WANG H J�� JIANG Y Y�� LU P��et al. An updated review at molecular pharmacological level for the mechanism of anti-tumor�� antioxidant and immunoregulatory action of silibinin��J��. Acta Pharm Sin(ҩѧѧ��)��2010�� 45 (4)413-421.
|
2013, Vol. 48 